Drugs / AMG 305
last change Jan 2026 re-read 3 minutes ago

AMG 305

Developed for
cancer
Investigated by
Amgen

Trials 1

202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05800964 Jun 2023 → Jan 2026 cancer Amgen Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AMG 305 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05800964 ↗
Route Intravenous “Short-term intravenous (IV) infusion” NCT05800964 ↗